Table 1.
Characteristics of Stage 1–3 patients who Received Chemotherapy*
| Neoadjuvant (N=98) | Adjuvant (N=233) | Total (N=331) | P-value (neoadjuvant compared with adjuvant) | |
|---|---|---|---|---|
| Age (mean, SD) | <.001 | |||
| 25−40 | 25 (25.8%) | 20 (8.6%) | 45 (13.6%) | |
| 41−50 | 27 (27.8%) | 59 (25.3%) | 89 (26.1%) | |
| 51−60 | 27 (27.8%) | 87 (37.3%) | 114 (34.6%) | |
| 61−80 | 18 (18.6%) | 67 (28.8%) | 85 (25.8%) | |
| Missing | 1 (1.0%) | 0 (0.0%) | 1 (0.3%) | |
| Race | 0.60 | |||
| White | 89 (90.8%) | 219 (94.0%) | 308 (93.1%) | |
| Black | 7 (7.1%) | 9 (3.9%) | 16 (4.8%) | |
| American Indian, Aleutian, or Eskimo | 0 (0.0%) | 1 (0.43%) | 1 (0.30%) | |
| Chinese | 0 (0.0%) | 2 (0.86%) | 2 (0.60%) | |
| Other Asian | 1 (1.0%) | 1 (0.43%) | 2 (0.60%) | |
| Missing | 1 (1.0%) | 1 (0.43%) | 2 (0.60%) | |
| Marital Status | 0.78 | |||
| Partnered | 73 (74.5%) | 177 (76.0%) | 250 (75.5%) | |
| Unpartnered | 25 (25.5%) | 56 (24.0%) | 81 (24.5%) | |
| Missing | 0 (0.0%) | 0 (0.0%) | 0 (0.0%) | |
| Currently Employed | 66 (67.4%) | 164 (70.4%) | 230 (69.5%) | 0.55 |
| Missing | 0 (0.0%) | 1 (0.4%) | 1 (0.30%) | |
| Yearly household income | 0.03 | |||
| Less than $100,000 | 54 (55.1%) | 164 (70.4%) | 218 (65.9%) | |
| Greater than $100,000 | 30 (30.6%) | 48 (20.6%) | 78 (23.6%) | |
| Missing/Prefer not to answer | 14 (14.3%) | 21 (9.0%) | 35 (10.6%) | |
| Education | 0.02 | |||
| High School/GED or less | 12 (12.4%) | 54 (23.2%) | 66 (19.9%) | |
| At least some College | 86 (87.8%) | 177 (80.0%) | 263 (79.5%) | |
| Missing/Prefer not to answer | 0 (0.0%) | 2 (0.86%) | 2 (0.6%) | |
| Rural (Non-Metropolitan Statistical Area) | 18 (18.4%) | 60 (25.8%) | 78 (23.6%) | 0.15 |
| Stage | 0.02 | |||
| 1 | 15 (15.3%) | 93 (39.9%) | 108 (32.6%) | |
| 2 | 59 (60.2%) | 104(44. 6%) | 163 (49.2%) | |
| 3 | 24 (24.5%) | 36 (15.5%) | 60 (18.1%) | |
| Missing | 0 (0.0%) | 0 (0.0%) | 0 | |
| (0.0%) | ||||
| HER2/HR status | 0.008 | |||
| HER2+/HR+ | 22 (22.5%) | 33 (14.2%) | 55 (16.6%) | |
| HER2+/HR- | 10 (10.2%) | 10 (4.3%) | 20 (6.0%) | |
| HER2-/HR+ | 43 (43.9%) | 146 (62.7%) | 189 (57.1%) | |
| HER2-/HR- | 20 (20.4%) | 37 (15.9%) | 57 (17.2%) | |
| Missing | 3 (3.1%) | 7 (3.0%) | 10 (3.0%) | |
| GPC site | 0.16 | |||
| 1 | 13 (13.3%) | 26 (11.2%) | 39 (11.8%) | |
| 2 | 5 (5.1%) | 20 (8.6%) | 25 (7.6%) | |
| 3 | 12 (12.2%) | 22 (9.4%) | 34 (10.3%) | |
| 4 | 9 (9.2%) | 34 (14.6%) | 43 (13.0%) | |
| 5 | 10 (10.2%) | 29 (12.5%) | 39 (11.8%) | |
| 6 | 14 (14.3%) | 38 (16.3%) | 52 (15.7%) | |
| 7 | 24 (24.5%) | 31 (13.3%) | 55 (16.6%) | |
| 8 | 11 (11.2%) | 33 (14.2%) | 44 (13.3%) |
*
All variables measured at time of diagnosis